

chain nodes :

7 9 10 11 12 13 17 19 20 22

ring nodes :

1 2 3 4 5 6

chain bonds :

7-9 9-10 12-13 19-20 20-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

7-9 9-10 12-13 19-20 20-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:[\*1],[\*2]

G2:O,S,NH

G3:O,NH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:CLASS10:CLASS11:Atom 12:CLASS  
13:Atom

17:CLASS19:CLASS20:CLASS22:CLASS26:Atom

Generic attributes :

10:

Saturation : Saturated

11:



Saturation : Unsaturated

13:

Saturation : Unsaturated

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10500485.str



chain nodes :  
 7 9 10 11 12 13 17 19 20 22  
 ring nodes :  
 1 2 3 4 5 6  
 chain bonds :  
 7-9 9-10 12-13 19-20 20-22  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 7-9 9-10 12-13 19-20 20-22  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 isolated ring systems :  
 containing 1 :

G1:[\*1],[\*2]

G2:O,S,NH

G3:O,NH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS  
 11:Atom 12:CLASS 13:Atom 17:CLASS 19:CLASS 20:CLASS 22:CLASS 26:Atom  
 Generic attributes :


11:

Saturation : Unsaturated

13:

$$\Rightarrow d \mid 11$$

L1	STR
----	-----



G3 O, NH

=> s ll sss sam

SAMPLE SCREEN SEARCH COMPLETED - 3653 TO ITERATE

```

54.7% PROCESSED      2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

27 ANSWERS

```



FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:   69436 TO   76684
PROJECTED ANSWERS:      565 TO    1407

```

L2                    27 SEA SSS SAM L1

$$\Rightarrow \Rightarrow$$

Uploading C:\Program Files\Stnexp\Queries\10500485 (a).str



chain nodes :  
 7 9 10 11 12 13 17 19 20 22  
 ring nodes :  
 1 2 3 4 5 6  
 chain bonds :  
 7-9 9-10 12-13 19-20 20-22  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 7-9 9-10 12-13 19-20 20-22  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 isolated ring systems :  
 containing 1 :

G1:[\*1],[\*2]

G2:O,S,NH

G3:O,NH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS  
 11:Atom 12:CLASS 13:Atom 17:CLASS 19:CLASS 20:CLASS 22:CLASS 26:Atom

Generic attributes :

10:

Saturation : Saturated


11:

Saturation : Unsaturated

13:  
Saturation : Unsaturated

L3 STRUCTURE UPLOADED

=> d 13  
L3 HAS NO ANSWERS  
L3 STR



G1 [@1],[@2]  
G2 O,S,NH  
G3 O,NH

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam'  
MISMATCHED QUOTE 'SAM''  
Quotation marks (or apostrophes) must be used in pairs,  
one before and one after the expression you are setting  
off or masking.

=> s 13 sss sam  
SAMPLE SEARCH INITIATED 16:06:07 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 3653 TO ITERATE

54.7% PROCESSED 2000 ITERATIONS 10 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 69436 TO 76684

10/500,485

PROJECTED ANSWERS: 109 TO 621

L4 10 SEA SSS SAM L3

=> => s 13 sss ful

FULL SEARCH INITIATED 16:06:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 73505 TO ITERATE

100.0% PROCESSED 73505 ITERATIONS

211 ANSWERS

SEARCH TIME: 00.00.01

L5 211 SEA SSS FUL L3

=> => s 15

L6 9 L5

=> d 16 1-9 bib,ab,hitstr

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:513632 CAPLUS  
 DN 145:23310  
 TI Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging  
 IN Gulati, Anil; Gulati, Kartike  
 PA The Board of Trustees of the University of Illinois, USA  
 SO PCT Int. Appl., 77 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006057988	A2	20060601	WO 2005-US42258	20051121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-629923P P 20041122


AB Methods of imaging tumors, such as breast tumors, are disclosed. The methods utilize an endothelin ETB receptor agonist or an endothelin ETA receptor antagonist, in combination with an imaging agent, to detect a tumor in mammals, including humans. Examples are provided on the effects of IRL-1620 and BQ-788 on tumor imaging and on tumor response to paclitaxel and doxorubicin.

IT 218600-86-3

RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)  
 (diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging)

RN 218600-86-3 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-methoxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)





L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:291975 CAPLUS  
 DN 140:315088  
 TI Endothelin antagonists for treating Alzheimer's disease and dementias of  
 vascular origin  
 IN Gulati, Anil  
 PA The Board of Trustees of the University of Illinois, USA  
 SO PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028634	A1	20040408	WO 2003-US28212	20030910
	WO 2004028634	C2	20040708		
	W:	AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003270446	A1	20040419	AU 2003-270446	20030910
	US 2004092427	A1	20040513	US 2003-659579	20030910
PRAI	US 2002-413539P	P	20020925		
	WO 2003-US28212	W	20030910		

AB A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.


IT 405307-47-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(endothelin antagonists for treating Alzheimer's disease and vascular dementia)

RN 405307-47-3 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:1007851 CAPLUS  
 DN 140:53448  
 TI Method and composition for potentiating the antipyretic action of a  
 nonopioid analgesic  
 IN Gulati, Anil  
 PA USA  
 SO U.S. Pat. Appl. Publ., 55 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003236235	A1	20031225	US 2003-459905	20030612
	WO 2004000357	A1	20031231	WO 2003-US19151	20030617
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003279180	A1	20040106	AU 2003-279180	20030617
PRAI	US 2002-390045P	P	20020619		
	WO 2003-US19151	W	20030617		

AB A composition and method of treating fever, and optionally treating pain, are disclosed. The composition and method utilize a non-opioid analgesic and an endothelin antagonist as active agents to treat fever in mammals, including humans. The composition also is useful in the prevention and treatment of stroke and other cardiovascular disorders, like myocardial infarction.


IT 218600-86-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and composition for potentiating antipyretic action of nonopioid analgesic)

RN 218600-86-3 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-methoxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:532650 CAPLUS  
 DN 139:85375  
 TI Preparation of novel alkanesulfonamides as endothelin antagonists  
 IN Bolli, Martin; Boss, Christoph; Clozel, Martine; Fischli, Walter; Weller, Thomas  
 PA Actelion Pharmaceuticals Ltd., Switz.  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Appl.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003055863	A1	20030710	WO 2002-EP13970	20021210
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2471220	AA	20030710	CA 2002-2471220	20021210
	AU 2002361033	A1	20030715	AU 2002-361033	20021210
	EP 1465875	A1	20041013	EP 2002-795133	20021210
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002015424	A	20041214	BR 2002-15424	20021210
	US 2005085639	A1	20050421	US 2004-500485	20021210
	HU 200500082	A2	20050428	HU 2005-82	20021210
	CN 1612864	A	20050504	CN 2002-826644	20021210
	JP 2005513155	T2	20050512	JP 2003-556394	20021210
	ZA 2004004927	A	20050926	ZA 2004-4927	20040622
	NO 2004003215	A	20040729	NO 2004-3215	20040729
PRAI	WO 2002-EP2	A	20020102		
	WO 2002-EP13970	W	20021210		

OS MARPAT 139:85375

AB The invention relates to novel alkanesulfonamides of formula I [R1 = alkyl; R2 = aryl, heteroaryl, alkyl; R3 = aryl, heteroaryl; R4 = H, CF3, alkyl, alkylamino, alkoxy, alkylthio, aryl, heteroaryl, cycloalkyl, etc.; X = O, bond; Y = O, NH, NHSO2, NHSO2NH, OCONH, NHCO2, NHCONH; Z = O, S, NH; n = 2-4]. The invention also concerns related aspects including processes for the preparation of the compds., pharmaceutical compns. containing one

or more of those compds. and especially their use as endothelin receptor antagonists in the treatment and prevention of diseases associated to the endothelin system. Thus, II was prepared from di-Et 2-(p-tolyl)malonate, ethane sulfonamide potassium salt and 2-chloro-5-bromopyrimidine. In competition binding studies, the IC50 value of II against ETA receptor was 3.96 nM and >1000 against ETB.

IT 556796-38-4P 556796-39-5P 556796-40-8P  
 556796-41-9P 556796-42-0P 556796-43-1P  
 556796-44-2P 556796-45-3P 556796-46-4P  
 556796-47-5P 556796-48-6P 556796-49-7P  
 556796-50-0P 556796-51-1P 556796-52-2P


556796-53-3P 556796-54-4P 556796-55-5P  
 556796-56-6P 556796-57-7P 556796-58-8P  
 556796-59-9P 556796-60-2P 556796-61-3P  
 556796-62-4P 556796-63-5P 556796-64-6P  
 556796-65-7P 556796-66-8P 556796-67-9P  
 556796-68-0P 556796-69-1P 556796-70-4P  
 556796-71-5P 556796-72-6P 556796-73-7P  
 556796-74-8P 556796-75-9P 556796-76-0P  
 556796-77-1P 556796-78-2P 556796-79-3P  
 556796-80-6P 556796-81-7P 556796-82-8P  
 556796-83-9P 556796-84-0P 556796-85-1P  
 556796-86-2P 556796-87-3P 556796-88-4P  
 556796-89-5P 556796-90-8P 556796-91-9P  
 556796-92-0P 556796-93-1P 556796-94-2P  
 556796-95-3P 556796-96-4P 556796-97-5P  
 556796-98-6P 556796-99-7P 556797-00-3P  
 556797-01-4P 556797-02-5P 556797-03-6P  
 556797-04-7P 556797-05-8P 556797-06-9P  
 556797-07-0P 556797-08-1P 556797-09-2P  
 556797-10-5P 556797-11-6P 556797-12-7P  
 556797-13-8P 556797-14-9P 556797-15-0P  
 556797-16-1P 556797-17-2P 556797-18-3P  
 556797-19-4P 556797-30-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine alkanesulfonamides as endothelin antagonists)


RN 556796-38-4 CAPLUS

CN Ethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-39-5 CAPLUS

CN Ethanesulfonamide, N-[5-(4-methylphenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-40-8 CAPLUS

CN Ethanesulfonamide, N-[6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-41-9 CAPLUS

CN 1-Propanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-42-0 CAPLUS

CN 1-Propanesulfonamide, N-[5-(4-methylphenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-43-1 CAPLUS

CN 1-Propanesulfonamide, N-[6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-44-2 CAPLUS

CN Ethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-45-3 CAPLUS

CN 1-Propanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-46-4 CAPLUS

CN 1-Propanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-47-5 CAPLUS

CN 1-Propanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-48-6 CAPLUS

CN Ethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 556796-49-7 CAPLUS


CN Ethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)






RN 556796-50-0 CAPLUS

CN Methanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-51-1 CAPLUS

CN Methanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-52-2 CAPLUS

CN Methanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-53-3 CAPLUS

CN Methanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-54-4 CAPLUS

CN Methanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-55-5 CAPLUS

CN Methanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-56-6 CAPLUS

CN Methanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-57-7 CAPLUS

CN Methanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-chloro-5-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-58-8 CAPLUS

CN Methanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-59-9 CAPLUS

CN Methanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-60-2 CAPLUS

CN Methanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-61-3 CAPLUS

CN 1-Butanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-62-4 CAPLUS

CN 1-Butanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-63-5 CAPLUS

CN 1-Butanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 556796-64-6 CAPLUS

CN 1-Butanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(3-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-65-7 CAPLUS

CN 1-Butanesulfonamide, N-[5-(3-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-66-8 CAPLUS

CN 1-Butanesulfonamide, N-[5-(3-methoxyphenoxy)-6-[2-[[5-(methoxythio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-67-9 CAPLUS

CN 1-Butanesulfonamide, N-[5-(3-methoxyphenoxy)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-68-0 CAPLUS

CN 1-Propanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556796-69-1 CAPLUS


CN 1-Propanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556796-70-4 CAPLUS


CN 1-Propanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 556796-71-5 CAPLUS

CN 1-Propanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-72-6 CAPLUS

CN 1-Propanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-chloro-5-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-73-7 CAPLUS

CN 1-Propanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-74-8 CAPLUS

CN 1-Propanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556796-75-9 CAPLUS


CN 1-Propanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556796-76-0 CAPLUS


CN Ethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-

methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-77-1 CAPLUS

CN Ethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-78-2 CAPLUS

CN Ethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-79-3 CAPLUS

CN Ethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-chloro-5-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-80-6 CAPLUS

CN Ethanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-81-7 CAPLUS

CN Ethanesulfonamide, N-[5-(2-chloro-5-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-82-8 CAPLUS

CN Methanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-83-9 CAPLUS

CN Methanesulfonamide, N-[6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-84-0 CAPLUS

CN Methanesulfonamide, N-[5-(4-methylphenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-85-1 CAPLUS

CN Methanesulfonamide, N-[6-[3-[(5-bromo-2-pyrimidinyl)oxy]propoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-86-2 CAPLUS

CN Methanesulfonamide, N-[6-[3-[(5-methoxy-2-pyrimidinyl)oxy]propoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-87-3 CAPLUS

CN Methanesulfonamide, N-[5-(4-methylphenyl)-6-[3-[[5-(methylthio)-2-pyrimidinyl]oxy]propoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-88-4 CAPLUS

CN Methanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-89-5 CAPLUS

CN Methanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-90-8 CAPLUS

CN Methanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-91-9 CAPLUS

CN Methanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-92-0 CAPLUS

CN Methanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-cyclopropyl-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556796-93-1 CAPLUS


CN Ethanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556796-94-2 CAPLUS


CN Ethanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 556796-95-3 CAPLUS

CN Ethanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methythio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-96-4 CAPLUS

CN Ethanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-97-5 CAPLUS

CN Ethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-2-cyclopropyl-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-98-6 CAPLUS

CN Ethanesulfonamide, N-[2-cyclopropyl-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556796-99-7 CAPLUS

CN Ethanesulfonamide, N-[2-cyclopropyl-5-(4-methylphenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-00-3 CAPLUS

CN Ethanesulfonamide, N-[2-cyclopropyl-5-(4-methylphenyl)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-01-4 CAPLUS

CN Ethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-chlorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-02-5 CAPLUS

CN Ethanesulfonamide, N-[5-(4-chlorophenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-03-6 CAPLUS

CN Ethanesulfonamide, N-[5-(4-chlorophenyl)-6-[2-[(5-(methylthio)-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-04-7 CAPLUS

CN Ethanesulfonamide, N-[5-(4-chlorophenyl)-6-[2-[(5-(methylsulfonyl)-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-05-8 CAPLUS

CN 1-Propanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-06-9 CAPLUS

CN 1-Propanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-07-0 CAPLUS

CN 1-Propanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-08-1 CAPLUS

CN 1-Propanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-09-2 CAPLUS

CN 1-Butanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-10-5 CAPLUS

CN 1-Butanesulfonamide, N-[6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-11-6 CAPLUS

CN 1-Butanesulfonamide, N-[5-(4-methylphenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-12-7 CAPLUS

CN 1-Butanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-2-cyclopropyl-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-13-8 CAPLUS

CN 1-Butanesulfonamide, N-[2-cyclopropyl-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-14-9 CAPLUS

CN 1-Butanesulfonamide, N-[2-cyclopropyl-5-(4-methylphenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556797-15-0 CAPLUS


CN 1-Butanesulfonamide, N-[2-cyclopropyl-5-(4-methylphenyl)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556797-16-1 CAPLUS


CN 1-Butanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 556797-17-2 CAPLUS

CN 1-Butanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-18-3 CAPLUS

CN 1-Butanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-19-4 CAPLUS

CN 1-Butanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[[5-(methylsulfonyl)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 556797-30-9 CAPLUS

CN 1-Propanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-chlorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 556797-22-9P 556797-25-2P 556797-27-4P  
556797-29-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine alkanesulfonamides as endothelin antagonists)


RN 556797-22-9 CAPLUS

CN Ethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-25-2 CAPLUS

CN 1-Propanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 556797-27-4 CAPLUS

CN Ethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 556797-29-6 CAPLUS


CN 1-Propanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)]-2,2'-bipyrimidin-4-yl- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:414077 CAPLUS  
 DN 139:957  
 TI Method and composition using an endothelin antagonist for potentiating an opiate analgesic  
 IN Gulati, Anil  
 PA USA  
 SO U.S. Pat. Appl. Publ., 55 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003100507	A1	20030529	US 2002-301449	20021121
	CA 2464768	AA	20030605	CA 2002-2464768	20021122
	WO 2003045434	A2	20030605	WO 2002-US37461	20021122
	WO 2003045434	A3	20030925		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2002348224	A1	20030610	AU 2002-348224	20021122
EP	1448233	A2	20040825	EP 2002-782353	20021122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR	2002014481	A	20040914	BR 2002-14481	20021122
JP	2005513033	T2	20050512	JP 2003-546935	20021122
CN	1646166	A	20050727	CN 2002-823570	20021122
ZA	2004003162	A	20050126	ZA 2004-3162	20040426
NO	2004002612	A	20040622	NO 2004-2612	20040622
PRAI	US 2001-333599P	P	20011127		
	WO 2002-US37461	W	20021122		
AB	A composition and methods for treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and methods use an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans.				
IT	218600-86-3 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (endothelin antagonist for potentiation of opiate analgesic)				
RN	218600-86-3 CAPLUS				
CN	Benzeneethanesulfonamide, N-[6-(2-methoxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)				



L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:814110 CAPLUS  
 DN 137:325425  
 TI Preparation of sulfonylaminopyrimidines as endothelin receptor antagonists.  
 IN Bolli, Martin; Boss, Christoph; Clozel, Martine; Fischli, Walter; Weller, Thomas  
 PA Actelion Pharmaceuticals Ltd., Switz.  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083650	A1	20021024	WO 2002-EP3947	20020409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	WO 2001-EP4169	W	20010411		

OS MARPAT 137:325425

AB Title compds. [I; R1 = aryl, heteroaryl; R2 = alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R3 = Ph, mono, di- or trisubstituted Ph substituted with alkyl, alkenyl, alkyloxy, CF<sub>3</sub>, halo, alkylthio, hydroxyalkyl, cyano, CO<sub>2</sub>H, alkyloxycarbonyl, alkanoyl, CHO; R4 = H, CF<sub>3</sub>, alkyl, alkylamino, alkyloxy, alkylsulfinyl, alkylthio, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylamino, alkylaminoalkyl, amino, aryl, heteroaryl, heterocyclyl, heterocyclylalkoxy, heterocyclyloxy, heterocyclylamino, heterocyclylalkylamino, heterocyclylthio, heterocyclylalkylthio, heterocyclylalkyl, cycloalkyl, cycloalkyloxy, cycloalkylalkoxy, cycloalkylamino, cycloalkylalkylamino, cycloalkylalkyl, cycloalkylsulfinyl; A = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, CH:CH, C.tplbond.C; T = O, S; X = O, S, CH<sub>2</sub>, bond; Y = O, S, NH; Q = (CH<sub>2</sub>)<sub>k</sub>, CH<sub>2</sub>C.tplbond.CCH<sub>2</sub>; k = 2, 3, 4; Z = O, NH], were prepared Thus, 2-picolinic acid azide and DMAP in CHCl<sub>3</sub> were stirred for 1 h at 70°; 2-phenylethenesulfonic acid [6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]amide (preparation given) was added and the resulting solution was stirred for 16 h at 70° to give pyridin-2-ylcarbamic acid 2-[5-(2-methoxyphenoxy)-6-(2-phenylethenesulfonylamino)-2-pyridin-4-ylpyrimidin-4-yl]oxyethyl ester. I inhibited binding of endothelin to ETA receptors with IC<sub>50</sub> = 1-14 nM.

IT 473536-93-5P 473536-94-6P 473536-95-7P  
 473536-96-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of sulfonylaminopyrimidines as endothelin receptor antagonists)

RN 473536-93-5 CAPLUS


CN Carbamic acid, 2-pyridinyl-, 2-[[[5-(2-methoxyphenoxy)-6-[(2-phenylethyl)sulfonyl]amino]-2-(4-pyridinyl)-4-pyrimidinyl]oxy]ethyl ester

(9CI) (CA INDEX NAME)




RN 473536-94-6 CAPLUS

CN Carbamic acid, 2-pyridinyl-, 2-[[5-(2-methoxyphenoxy)-2-(4-morpholinyl)-6-[[2-phenylethyl)sulfonyl]amino]-4-pyrimidinyl]oxy]ethyl ester (9CI) (CA INDEX NAME)




RN 473536-95-7 CAPLUS

CN Carbamic acid, 2-pyridinyl-, 2-[[5-(2-methoxyphenoxy)-6-[[2-phenylethyl)sulfonyl]amino]-2-pyrazinyl-4-pyrimidinyl]oxy]ethyl ester (9CI) (CA INDEX NAME)



RN 473536-96-8 CAPLUS

CN Carbamic acid, 2-pyridinyl-, 2-[[5-(2-methoxyphenoxy)-2-(4-morpholinyl)-6-[[[2-(2-thienyl)ethyl]sulfonyl]amino]-4-pyrimidinyl]oxy]ethyl ester (9CI)  
(CA INDEX NAME)



IT 405307-45-1P 405307-49-5P 405307-51-9P

405307-66-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(intermediate; preparation of sulfonylaminopyrimidines as endothelin  
receptor antagonists)

RN 405307-45-1 CAPLUS


CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 405307-49-5 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrazinyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-51-9 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405307-66-6 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:240744 CAPLUS

DN 136:263176

TI Preparation of novel arylalkylsulfonamides as endothelin receptor antagonists

IN Weller, Thomas; Bolli, Martin; Boss, Christoph; Clozel, Martine; Fischli, Walter

PA Actelion Pharmaceuticals Ltd., Switz.

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

*Common In*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024665	A1	20020328	WO 2001-EP9894	20010828
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2423351	AA	20020328	CA 2001-2423351	20010828
	AU 2002012171	A5	20020402	AU 2002-12171	20010828
	EP 1322624	A1	20030702	EP 2001-980288	20010828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001014082	A	20030722	BR 2001-14082	20010828
	HU 200303364	A2	20040301	HU 2003-3364	20010828
	JP 2004509874	T2	20040402	JP 2002-529075	20010828
	NZ 524172	A	20040924	NZ 2001-524172	20010828
	CN 1633418	A	20050629	CN 2001-815896	20010828
	NO 2003001332	A	20030324	NO 2003-1332	20030324
	ZA 2003002292	A	20040630	ZA 2003-2292	20030324
	US 2004102464	A1	20040527	US 2003-381568	20030325
	US 7091201	B2	20060815		
PRAI	WO 2000-EP9327	W	20000925		
	WO 2001-EP9894	W	20010828		

X wo ODP

OS MARPAT 136:263176

AB Title compds. [I; R1 = C<sub>6</sub>H<sub>5</sub>, 2-thienyl, 2-pyridyl; n = 1, 2, 3; R2 = (un)substituted-2-pyrimidyl, (un)substituted-2-pyridyl, (un)substituted-Ph; m = 2, 3; X = R3, OR4; R3 = substituted-phenyl; R4 = 2-CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>, 3-CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>; R5 = H, 2-pyrimidyl, 4-pyridyl, 4-morpholinyl, 2-pyrazinyl] and pharmaceutically acceptable salts are prepared and their use as active ingredients in the preparation of pharmaceutical compns. are disclosed. The invention also concerns related aspects including processes for the preparation of the compds., pharmaceutical compns.

containing one

or more of those compds., require mixed ETA and ETB blocking for treatment, and especially their use as endothelin receptor antagonists. Thus, the title compound II was prepared from 2-(p-tolyl)malonic acid di-Et ester, formamidine, 2-phenylethanesulfonyl chloride, and 2-chloro-pyrimidine via cyclization, chloronation, sulfonation, displacement, etc.

IT 405305-52-4P 405305-57-9P 405305-60-4P  
405305-62-6P 405305-64-8P 405305-66-0P


405305-68-2P 405305-70-6P 405305-72-8P  
 405305-74-0P 405305-76-2P 405305-78-4P  
 405305-80-8P 405305-82-0P 405305-84-2P  
 405305-86-4P 405305-88-6P 405305-90-0P  
 405305-91-1P 405305-94-4P 405305-97-7P  
 405305-99-9P 405306-01-6P 405306-03-8P  
 405306-05-0P 405306-07-2P 405306-09-4P  
 405306-11-8P 405306-13-0P 405306-15-2P  
 405306-17-4P 405306-19-6P 405306-21-0P  
 405306-23-2P 405306-25-4P 405306-27-6P  
 405306-29-8P 405306-31-2P 405306-33-4P  
 405306-35-6P 405306-37-8P 405306-39-0P  
 405306-41-4P 405306-43-6P 405306-45-8P  
 405306-47-0P 405306-49-2P 405306-51-6P  
 405306-53-8P 405306-55-0P 405306-57-2P  
 405306-59-4P 405306-61-8P 405306-63-0P  
 405306-65-2P 405306-67-4P 405306-69-6P  
 405306-71-0P 405306-73-2P 405306-75-4P  
 405306-77-6P 405306-79-8P 405306-80-1P  
 405306-81-2P 405306-82-3P 405306-84-5P  
 405306-86-7P 405306-88-9P 405306-90-3P  
 405306-92-5P 405306-94-7P 405306-96-9P  
 405306-98-1P 405307-00-8P 405307-02-0P  
 405307-04-2P 405307-06-4P 405307-08-6P  
 405307-10-0P 405307-12-2P 405307-14-4P  
 405307-16-6P 405307-18-8P 405307-20-2P  
 405307-22-4P 405307-24-6P 405307-26-8P  
 405307-28-0P 405307-33-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(Preparation of arylalkylsulfonamides as endothelin receptor antagonists)


RN 405305-52-4 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(4-methylphenyl)-6-[2-(2-  
 pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-57-9 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(4-methylphenyl)-6-[2-[[5-(trifluoromethyl)-  
 2-pyridinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-60-4 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-(4-bromophenoxy)ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-62-6 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-(2-pyrimidinyl)ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405305-64-8 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405305-66-0 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-(9CI) (CA INDEX NAME)




RN 405305-68-2 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]-(9CI) (CA INDEX NAME)




RN 405305-70-6 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(4-methylphenyl)-6-[2-[(5-methyl-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-72-8 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-74-0 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405305-76-2 CAPLUS


CN Benzeneethanesulfonamide, N-[5-(4-methylphenyl)-6-[2-[(5-methyl-2-pyrimidinyl)oxy]ethoxy]-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405305-78-4 CAPLUS


CN Benzeneethanesulfonamide, N-[6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 405305-80-8 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405305-82-0 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405305-84-2 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405305-86-4 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-88-6 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-90-0 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(4-bromophenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-91-1 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(3,4-dimethylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-94-4 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(3,4-dimethylphenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-97-7 CAPLUS

CN Benzenesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2,4-dimethylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405305-99-9 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2,4-dimethylphenyl)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-01-6 CAPLUS

CN    Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-pyridinyl)-6-[2-(2-pyrimidinylloxy)ethoxy]-4-pyrimidinyl]- (9CI)    (CA INDEX NAME)




RN 405306-03-8 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-05-0 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-07-2 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-09-4 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405306-11-8 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methyl-2-pyrimidinyl)oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405306-13-0 CAPLUS

CN	Benzenethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)
----	--



RN 405306-15-2 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(trifluoromethyl)-2-pyrimidinyl]oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI)  
(CA INDEX NAME)




RN 405306-17-4 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(trifluoromethyl)-2-pyrimidinyl]oxy]ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI)




(CA INDEX NAME)




RN 405306-19-6 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-pyrazinyl-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-21-0 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-pyrazinyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-23-2 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-2-pyrazinyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-25-4 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-2-pyrazinyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-27-6 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-morpholinyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-29-8 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-31-2 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-33-4 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-35-6 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-(2-pyrimidinyl)ethoxy]ethoxy]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 405306-37-8 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-39-0 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-41-4 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-(trifluoromethyl)-2-pyridinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-43-6 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(3-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-45-8 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(3-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-47-0 CAPLUS

CN Benzeneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(3-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-49-2 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(3-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405306-51-6 CAPLUS


CN 2-Thiopheneethanesulfonamide, N-[6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405306-53-8 CAPLUS


CN 2-Thiopheneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 405306-55-0 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-57-2 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[5-(4-chlorophenyl)-6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-59-4 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-chlorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-61-8 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[5-(4-chlorophenyl)-6-[2-[(5-methyl-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-63-0 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[5-(4-chlorophenyl)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-65-2 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-[2-[(5-chloro-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-67-4 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-69-6 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-71-0 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-73-2 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-[(5-methoxy-2-pyrimidinyl)oxy]ethoxy]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-75-4 CAPLUS

CN 2-Pyridineethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-pyridinyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-77-6 CAPLUS

CN 2-Pyridineethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-79-8 CAPLUS

CN Benzenemethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-pyridinyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-80-1 CAPLUS

CN Benzenemethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-81-2 CAPLUS

CN Benzenemethanesulfonamide, N-[6-[2-(4-bromophenoxy)ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-82-3 CAPLUS

CN Benzenemethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-(2-pyrimidinyl)ethoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 405306-84-5 CAPLUS


CN Benzenemethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 405306-86-7 CAPLUS


CN Benzenemethanesulfonamide, N-[6-[2-(4-bromophenoxy)ethoxy]-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)






RN 405306-88-9 CAPLUS

CN Benzenemethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-morpholinyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-90-3 CAPLUS

CN Benzenemethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405306-92-5 CAPLUS

CN Benzenemethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-pyridinyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 405306-94-7 CAPLUS

CN Benzenemethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 405306-96-9 CAPLUS

CN Benzenemethanesulfonamide, N-[5-(2-methoxyphenoxy)-2-pyrazinyl-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 405306-98-1 CAPLUS

CN Benzenemethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-pyrazinyl-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 405307-00-8 CAPLUS

CN Benzenepropanesulfonamide, N-[5-(4-methylphenyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-02-0 CAPLUS

CN Benzenepropanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-04-2 CAPLUS

CN Benzenepropanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-pyridinyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-06-4 CAPLUS

CN Benzenepropanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-08-6 CAPLUS

CN Benzenepropanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[2-(2-pyrimidinyl)ethoxy]-2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405307-10-0 CAPLUS

CN Benzenepropanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405307-12-2 CAPLUS

CN Benzenepropanesulfonamide, N-[5-(2-methoxyphenoxy)-2-(4-morpholinyl)-6-[2-(2-pyrimidinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-14-4 CAPLUS

CN Benzenepropanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-16-6 CAPLUS

CN Benzenemethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[3-(2-pyrimidinyl)oxy]propoxy][2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 405307-18-8 CAPLUS


CN Benzenemethanesulfonamide, N-[5-(2-methoxyphenoxy)-6-[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]propoxy][2,2'-bipyrimidin]-4-yl]- (9CI)  
(CA INDEX NAME)



RN 405307-20-2 CAPLUS


CN Benzenepropanesulfonamide, N-[6-[3-[(5-bromo-2-pyrimidinyl)oxy]propoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 405307-22-4 CAPLUS

CN Benzenepropanesulfonamide, N-[6-[3-[(5-bromo-2-pyridinyl)oxy]propoxy]-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-24-6 CAPLUS

CN Benzenepropanesulfonamide, N-[5-(4-methylphenyl)-6-[3-[(5-(trifluoromethyl)-2-pyridinyl)oxy]propoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405307-26-8 CAPLUS


CN Benzenepropanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405307-28-0 CAPLUS


CN Benzenepropanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

phenyl[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 405307-33-7 CAPLUS

CN 2-Pyridineethanesulfonamide, N-[6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-5-(2-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 403604-96-6P 405307-34-8P 405307-35-9P  
 405307-37-1P 405307-39-3P 405307-41-7P  
 405307-43-9P 405307-45-1P 405307-47-3P  
 405307-49-5P 405307-51-9P 405307-53-1P  
 405307-55-3P 405307-57-5P 405307-59-7P  
 405307-61-1P 405307-64-4P 405307-66-6P  
 405307-68-8P 405307-70-2P 405307-73-5P  
 405307-75-7P 405307-77-9P 405307-79-1P  
 405307-81-5P 405307-83-7P 405307-85-9P  
 405307-87-1P 405307-89-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(Preparation of arylalkylsulfonamides as endothelin receptor antagonists)


RN 403604-96-6 CAPLUS

CN Benzenemethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)




RN 405307-34-8 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-35-9 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-37-1 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-39-3 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(4-bromophenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-41-7 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(3,4-dimethylphenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-43-9 CAPLUS

CN Benzeneethanesulfonamide, N-[5-(2,4-dimethylphenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-45-1 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-47-3 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)]-2-pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 405307-49-5 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrazinyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-51-9 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-53-1 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-55-3 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-57-5 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-59-7 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-61-1 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[5-(4-chlorophenyl)-6-(2-hydroxyethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-64-4 CAPLUS

CN 2-Thiopheneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405307-66-6 CAPLUS


CN 2-Thiopheneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405307-68-8 CAPLUS


CN 2-Pyridineethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)






RN 405307-70-2 CAPLUS

CN Benzenemethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-73-5 CAPLUS

CN Benzenemethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-75-7 CAPLUS

CN Benzenemethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 405307-77-9 CAPLUS

CN Benzenemethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrazinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 405307-79-1 CAPLUS


CN Benzenepropanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405307-81-5 CAPLUS


CN Benzenepropanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-

(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-83-7 CAPLUS

CN Benzenepropanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-85-9 CAPLUS

CN Benzenepropanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 405307-87-1 CAPLUS

CN Benzenemethanesulfonamide, N-[6-(3-hydroxypropoxy)-5-(2-methoxyphenoxy)-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 405307-89-3 CAPLUS

CN Benzenepropanesulfonamide, N-[6-(3-hydroxypropoxy)-5-(4-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:845783 CAPLUS

DN 136:232269

TI Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists

AU Harada, Hironori; Kazami, Jun-Ichi; Watanuki, Susumu; Tsuzuki, Ryuji; Sudoh, Katsumi; Fujimori, Akira; Sanagi, Masanao; Orita, Masaya; Nakahara, Hideaki; Shimaya, Jun; Tsukamoto, Shin-Ichi; Tanaka, Akihiro; Yanagisawa, Isao

CS Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305-8585, Japan

SO Bioorganic & Medicinal Chemistry (2001), 9(11), 2955-2968  
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 136:232269

AB In the previous paper, a series of 2-phenylethenesulfonamide derivs., a novel class of ETA-selective endothelin (ET) receptor antagonists, including a 2-methoxyethoxy derivative and a 2-fluoroethoxy derivative, were described. In this paper, further details of structure-activity relationships (SARs) of the two regions of the mol. in the above compds., which were the alkoxy region at the 6-position of the core pyrimidine ring and the 2-phenylethenesulfonamide region, were described. In these modifications, replacement of the 2-fluoroethoxy group with a methoxy group and replacement of the 2-phenylethenesulfonamide group with a 2-(pyridin-3-yl)ethanesulfonamide group or 2-phenylethanesulfonamide group were well tolerated both in the ETA binding affinity and ETA selectivity. Among them, N-[6-methoxy-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-2-phenylethenesulfonamide (I) showed good oral activity. After oral administration, I inhibited the big ET-1 induced pressor response in conscious rats at 0.3 mg/kg with a duration of >6.5 h. I also exhibited a potent antagonistic activity in the pithed rats.


IT 403604-96-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and activity of N-[(methoxyphenoxy)-2,2'-bipyrimidin-4-yl]ethanesulfonamide derivs. as orally active endothelin-A receptor antagonists)

RN 403604-96-6 CAPLUS

CN Benzenemethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:9821 CAPLUS  
 DN 130:81521  
 TI Preparation of N-pyrimidinylalkanesulfonamides as endothelin antagonists  
 IN Harada, Hironori; Kazami, Jun-ichi; Watanuki, Susumu; Fujimori, Akira  
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2

DT Patent  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9857938	A1	19981223	WO 1998-JP2723	19980618
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9880356	A1	19990104	AU 1998-80356	19980618
PRAI	JP 1997-162449	A	19970619		
	WO 1998-JP2723	W	19980618		


OS MARPAT 130:81521

AB The title compds. I [n is 1 or 2; A represents an optionally substituted aryl group or an optionally substituted heteroaryl group; B represents an optionally substituted Ph group; R1 represents a lower alkyl, lower alkenyl, or lower alkynyl group (these groups each being optionally substituted by one to three groups selected from the group consisting of halogen atoms and hydroxy, lower alkyl-O-, carboxyl, lower alkyl-O-CO-, and cycloalkyl groups); X represents a group represented by O, S, or NH; and Y represents O or S] are prepared In an in vitro test for ET-1 antagonism, the title compound II showed IC50 of 3.1 nM.

IT 218600-86-3P 218600-98-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of N-pyrimidinylalkanesulfonamides as endothelin antagonists)

RN 218600-86-3 CAPLUS


CN Benzeneethanesulfonamide, N-[6-(2-methoxyethoxy)-5-(2-methoxyphenoxy) [2,2'-bipyrimidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 218600-98-7 CAPLUS

CN Benzeneethanesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy) [2,2'-

bipyrimidin]-4-yl]-2,4,6-trimethyl- (9CI) (CA INDEX NAME)



RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; =&gt; d his

(FILE 'HOME' ENTERED AT 16:02:58 ON 05 DEC 2006)

FILE 'REGISTRY' ENTERED AT 16:03:08 ON 05 DEC 2006

L1               STRUCTURE UPLOADED  
 L2               27 S L1 SSS SAM  
 L3               STRUCTURE UPLOADED  
 L4               10 S L3 SSS SAM  
 L5               211 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 16:06:51 ON 05 DEC 2006

L6               9 S L5

FILE 'CAOLD' ENTERED AT 16:07:23 ON 05 DEC 2006

=&gt; s 15

L7               0 L5

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

216.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-6.75

STN INTERNATIONAL LOGOFF AT 16:07:36 ON 05 DEC 2006